GHRP-6 Acetate
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
GHRP-6 does not introduce a foreign instruction. It speaks in a dialect the hypothalamic-pituitary axis evolved to receive – mimicking ghrelin’s secretagogue function with a synthetic hexapeptide that binds the growth hormone secretagogue receptor with high affinity. The result is a coordinated, pulsatile release of endogenous growth hormone rather than a pharmacological flood. Understanding that distinction is the beginning of understanding GHRP-6.
GHSR-1a agonism is the primary action of GHRP-6, binding pituitary somatotrophs, activating Gq-phospholipase C signaling, and triggering pulsatile GH exocytosis through intracellular calcium mobilization. Somatostatin tone and receptor desensitization impose a physiologic ceiling on the size of each pulse.
Hypothalamic co-signaling amplifies the pituitary response by augmenting endogenous GHRH release when GHRP-6 engages GHSR-1a on relevant hypothalamic neurons. This convergence of signals is the mechanistic basis for its frequent pairing with GHRH analogues in the literature.
Orexigenic signaling accounts for the compound’s characteristic hunger response, with GHSR-1a engagement in the hypothalamus and vagal afferents activating arcuate NPY/AgRP pathways. Among the GHRP series, this appetite effect is generally regarded as the most pronounced.
CD36-mediated activity represents a separate GH-independent pathway, with GHRP-6 binding CD36 on cardiomyocytes and activating Src-family kinase cascades that attenuate NF-κB-associated apoptosis in ischemia-reperfusion models. This mechanism is distinct from the somatotropic axis and is studied primarily in preclinical settings.
What we observe
Seen with GHRP-6: appetite and GH shifts
The outcomes attributed to GHRP-6 span pituitary endocrinology, body composition, appetite physiology, and cytoprotection. The patterns below reflect observations from peer-reviewed research, not clinical claims. Individual response is shaped by age, somatostatin tone, nutritional status, and concurrent signaling context.
01
Pulsatile GH Secretion
02
IGF-1 Elevation
03
Appetite Stimulation
04
Lean Mass Preservation
05
Cardiac Cytoprotection
06
Sleep Architecture Support
Evidence
The data on GHRP-6
GHRP-6 carries one of the longest research histories of any synthetic secretagogue, with four decades of published pharmacology spanning pituitary physiology, body composition, and cytoprotection. The studies below represent methodologically significant entries in that record. They are presented for educational orientation, not as a basis for clinical decision-making.
Growth Hormone-Releasing Peptide-6 Stimulates GH Secretion in Normal and Short-Stature Children
A dose-escalation study in 24 pediatric subjects demonstrated that subcutaneous GHRP-6 produced robust, dose-dependent GH pulses with peak responses at 100 µg/kg. Co-administration with GHRH produced supra-additive GH release, establishing the synergistic signaling model that has guided secretagogue combination research since.
GHRP-6 Reduces Myocardial Infarct Size and Preserves Cardiac Function in a Rat Ischemia-Reperfusion Model
Intravenous GHRP-6 administered prior to coronary occlusion in Sprague-Dawley rats reduced infarct area as a percentage of risk zone by approximately 38% compared to vehicle controls. Ejection fraction at 24 hours post-reperfusion was significantly preserved. Hypophysectomized animals showed comparable protection, indicating a GH-independent cytoprotective mechanism.
Repeated Administration of GHRP-6 Sustains GH Pulsatility and Elevates IGF-1 in Healthy Elderly Men
A four-week, double-blind, placebo-controlled study in 18 men aged 60–72 found that twice-daily subcutaneous GHRP-6 (1 µg/kg) maintained GH pulse amplitude without evidence of receptor desensitization and produced a statistically significant 28% increase in serum IGF-1 from baseline. Appetite scores increased in the active arm, consistent with GHSR-1a orexigenic activity.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 300–900 mcg total (split into 3 doses with gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days.
- Do not freeze reconstituted solution - repeated freeze-thaw cycles degrade peptide integrity.
- Keep vials in opaque secondary packaging; UV exposure accelerates oxidative degradation of the tryptophan residues.
- Discard if solution appears cloudy, discolored, or contains visible particulate matter.
Side effects
What members describe
- Pronounced appetite stimulation - the most consistently reported effect; mechanistically expected via GHSR-1a orexigenic signaling; dose-dependent.
- Transient elevation of cortisol and prolactin - co-secreted alongside GH at the pituitary level; typically modest and self-limiting at research doses.
- Water retention and mild peripheral edema - a downstream consequence of GH-mediated sodium retention; more common at higher doses or with frequent administration.
- Injection-site reactions - transient erythema, induration, or discomfort; rotate sites with each administration.
- Transient hypoglycemia - GH secretion can transiently suppress insulin sensitivity; administer in a fasted but not depleted state; monitor in subjects with metabolic vulnerability.
Contradictions
Reasons to abstain
- Active malignancy or personal history of hormone-sensitive neoplasm - GH and IGF-1 elevation may support tumor proliferation; absolute contraindication in oncology contexts.
- Diabetic retinopathy or uncontrolled diabetes mellitus - GH-mediated insulin resistance may worsen glycemic control and exacerbate retinal pathology.
- Pregnancy and lactation - no safety data; GHSR-1a agonism during fetal development is unstudied in humans.
- Concurrent exogenous GH therapy - additive GH axis stimulation increases risk of acromegalic side effects and IGF-1 excess.
- Pituitary adenoma or hypothalamic-pituitary axis pathology - stimulation of a dysregulated axis carries unpredictable risk; endocrinological evaluation required before any use.
Synergies
What goes well with GHRP-6
GHRP-6 is rarely studied in isolation in contemporary research protocols. Its most meaningful combinations are those where the mechanistic logic is explicit – where each compound addresses a distinct node in the same signaling architecture. The pairings below reflect patterns observed in the literature and in investigational practice. They are not prescriptions.
FAQ
Your questions, patiently answered
Both are GHSR-1a agonists, but their selectivity profiles diverge meaningfully. GHRP-6 co-stimulates cortisol and prolactin secretion alongside GH – a consequence of its broader receptor engagement profile. Ipamorelin was specifically engineered to minimize these co-secretions, producing a cleaner GH pulse. GHRP-6’s appetite stimulation is also considerably more pronounced. Neither is universally superior; the choice depends on what the protocol is designed to study or address.
Because GHSR-1a is the canonical ghrelin receptor, and ghrelin is the body’s primary orexigenic peptide hormone. GHRP-6 binding at hypothalamic GHSR-1a activates NPY/AgRP orexigenic neurons – the same pathway that drives hunger before meals. This is not an off-target effect; it is a direct pharmacological consequence of the receptor being agonized. In cachexia research, this property is considered therapeutically useful. In other contexts, it requires dietary management.
Yes, substantially. Elevated blood glucose and free fatty acids both increase somatostatin tone, which blunts the GH pulse. The literature consistently shows that GHRP-6 administered in a fasted state produces significantly larger GH responses than post-prandial administration. A minimum two-hour fast before injection is the standard research protocol condition.
The available evidence does not support significant axis suppression at research doses. Unlike exogenous GH, which suppresses endogenous secretion via negative feedback, GHRP-6 works by amplifying the pituitary’s own release machinery. The four-week study in elderly men (European Journal of Endocrinology, 1997) found maintained GH pulsatility without desensitization. Prolonged high-dose use remains less well-characterized, and periodic cycling is a common investigational practice.
GHRP-6 Acetate refers to the acetate counter-ion paired with the hexapeptide in its lyophilized form – a standard pharmaceutical salt form that improves stability and solubility. The pharmacologically active moiety is the hexapeptide itself; the acetate contributes to formulation stability rather than receptor activity. The CAS number 87616-84-0 refers specifically to this salt form.
This is one of pharmacology’s more elegant reversals. GHRP-6 was synthesized in 1980 as a synthetic enkephalin analogue with unexpected GH-releasing properties. Its receptor – GHSR-1a – was identified and cloned in 1996. The endogenous ligand for that receptor, ghrelin, was not discovered until 1999 by Kojima et al. at Kurume University. GHRP-6 thus preceded the discovery of the very hormone it mimics – a synthetic key that revealed the lock, which then revealed the natural key. The historical sequence is a useful reminder that pharmacological tools often illuminate biology rather than merely exploit it.
In the same family
Further reading in the curriculum - adjacent peptides worth understanding.
Sourcing · Independently verified
When you're ready, source thoughtfully.